U.S. COVID-19 Update eNewsletter
December 6, 2021

Vaccine Manufacturers Work to Respond to Any Omicron Variant Threats
With concerns heightened by the appearance of the B.1.1.529 (Omicron) variant of SARS-CoV-2, major vaccine manufacturers had some reassuring news: They are well on their way to developing products that will act against the COVID-19 mutation. Moderna quickly announced updates to its strategy to combat SARS-CoV-2 variants of concern, given the emergence of the Omicron variant. Read more.


Inhaled Steroids Still Promising, Although Study Did Not Meet Endpoint
Oral steroids have been shown to have a positive effect in COVID-19 patients, but what about inhaled steroids? A study of ciclesonide did not meet its endpoint—time to alleviation of symptoms in the nonhospitalized—but it met a secondary endpoint, which was fewer subsequent emergency department visits or hospital admissions for COVID-19 symptoms. Read more.

Controlled Blood Sugar, Drug Combos Protective Against COVID-19 for T2D Patients
Whether type 2 diabetes (T2D) patients are likely to end up with severe cases of COVID-19 depends on some key factors. Find out how a new study determined that patients with well-controlled blood sugar and those using certain drug combinations—such as metformin and insulin together—were less likely to end up in intensive care. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App